Appendix cancer differential diagnosis: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
'''For the WikiDoc page for this topic, click [[Appendix cancer|here]]''' | '''For the WikiDoc page for this topic, click [[Appendix cancer|here]]''' | ||
Line 15: | Line 16: | ||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
! colspan="2" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;"|Diseases | ! colspan="2" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
| colspan="7" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="7" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
|- | |- | ||
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | | colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | ||
Line 98: | Line 98: | ||
* CK 19 | * CK 19 | ||
* CK 20 | * CK 20 | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid tumor<sup>2</sup> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid tumor<sup>2</sup> | ||
Line 144: | Line 142: | ||
'''IHC''' might be positive for '''S100''' | '''IHC''' might be positive for '''S100''' | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px;" |Goblet cell carcinoid | | style="background: #DCDCDC; padding: 5px;" |Goblet cell carcinoid | ||
Line 189: | Line 185: | ||
::*Nuclear pleomorphism | ::*Nuclear pleomorphism | ||
::*Increased mitotic activity | ::*Increased mitotic activity | ||
|- | |- | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;"|Diseases | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain''' | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain''' | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size | ||
Line 206: | Line 201: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix Mucocele | | rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix Mucocele | ||
Line 243: | Line 237: | ||
| rowspan="4" style="background: #F5F5F5; padding: 5px;" |N/A | | rowspan="4" style="background: #F5F5F5; padding: 5px;" |N/A | ||
| style="background: #F5F5F5; padding: 5px;" |Similar to hyperplastic colon polyp | | style="background: #F5F5F5; padding: 5px;" |Similar to hyperplastic colon polyp | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px;" |Simple or retention cyst | | style="background: #DCDCDC; padding: 5px;" |Simple or retention cyst | ||
Line 255: | Line 248: | ||
| style="background: #F5F5F5; padding: 5px;" |N/A | | style="background: #F5F5F5; padding: 5px;" |N/A | ||
| style="background: #F5F5F5; padding: 5px;" |Degenerative epithelial changes because of obstruction | | style="background: #F5F5F5; padding: 5px;" |Degenerative epithelial changes because of obstruction | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px;" | Mucinous cystadenomas | | style="background: #DCDCDC; padding: 5px;" | Mucinous cystadenomas | ||
Line 277: | Line 269: | ||
* Histologically benign | * Histologically benign | ||
* Similar to colon adenomatous polyps or villous adnomas | * Similar to colon adenomatous polyps or villous adnomas | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px;" | Mucinous cystadenocarcinomas | | style="background: #DCDCDC; padding: 5px;" | Mucinous cystadenocarcinomas | ||
Line 294: | Line 285: | ||
* Glandular invasion into the stoma | * Glandular invasion into the stoma | ||
* Pseudomyxoma peritonei | * Pseudomyxoma peritonei | ||
|- | |- | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;"|Diseases | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain''' | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain''' | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size | ||
Line 311: | Line 301: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Ovarian cancer differential diagnosis|Ovarian cancer]] | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Ovarian cancer differential diagnosis|Ovarian cancer]] | ||
Line 370: | Line 359: | ||
| style="background: #F5F5F5; padding: 5px;" | N/A | | style="background: #F5F5F5; padding: 5px;" | N/A | ||
| style="background: #F5F5F5; padding: 5px;" | Depends on the tumor type. You may find the details [[Ovarian cancer differential diagnosis|here]]. | | style="background: #F5F5F5; padding: 5px;" | Depends on the tumor type. You may find the details [[Ovarian cancer differential diagnosis|here]]. | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Colorectal cancer]] | | colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Colorectal cancer]] | ||
Line 419: | Line 407: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Depends on the tumor type.. You will find more information [[Colorectal cancer differential diagnosis|here]] | * Depends on the tumor type.. You will find more information [[Colorectal cancer differential diagnosis|here]] | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Pseudomyxoma peritonei differential diagnosis|Pseudomyxoma peritonei]] | | colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Pseudomyxoma peritonei differential diagnosis|Pseudomyxoma peritonei]] | ||
Line 457: | Line 444: | ||
*:* [[MUC2]] | *:* [[MUC2]] | ||
*:* MUC5AC | *:* MUC5AC | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Carcinoid syndrome]] | | colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Carcinoid syndrome]] | ||
Line 514: | Line 499: | ||
** CD56 and PGP ( less specific) | ** CD56 and PGP ( less specific) | ||
** PDX1 and ISL1 | ** PDX1 and ISL1 | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Appendicitis differential diagnosis|Appendicitis]] <sup>3</sup> | | colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Appendicitis differential diagnosis|Appendicitis]] <sup>3</sup> | ||
Line 557: | Line 539: | ||
| style="background: #F5F5F5; padding: 5px;" |[[Tc-99m]] labeled anti-[[CD15]] [[antibodies]] | | style="background: #F5F5F5; padding: 5px;" |[[Tc-99m]] labeled anti-[[CD15]] [[antibodies]] | ||
| style="background: #F5F5F5; padding: 5px;" |Evidences of [[inflammation]] | | style="background: #F5F5F5; padding: 5px;" |Evidences of [[inflammation]] | ||
|- | |- | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;"|Diseases | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain''' | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdominal pain''' | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size | ||
Line 575: | Line 555: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other diagnostic studies and imaging modalities | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|} | |} | ||
Revision as of 17:00, 18 February 2019
For the WikiDoc page for this topic, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Appendix cancer must be differentiated from benign appendix lesions (mucocele, acute appendicitis), colorectal cancers, adenexal masses (ovarian tumors), and carcinoid tumors of the other organs.
Differentiating appendix cancer from other Diseases
- Appendix cancer must be differentiated from benign appendix lesions (mucocele, acute appendicitis), colorectal cancers, adenexal masses (ovarian tumors), and carcinoid tumors of the other organs.
- As appendix cancer manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype.
- Carcinoid tumors must be differentiated from other diseases that causecarcinoid syndrome, such as palpitation, facial flushing, diarrhea, .
- In contrast, adenocarcinomas and cystadenocarcinomas must be differentiated from other diseases that cause acute appendicitis or present with pseudomyxoma peritonei, such as colorectal cancers, appendix mucoceles.
Diseases | Clinical manifestations | Para-clinical findings | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||
Abdominal pain | Change in girdle size | Change in bowel habits | Other symptoms | Abdominal mass | abdominal tenderness | Other physical examination findings | Urinary 5-hydroxyindoleacetic acid (5-HIAA) and/or Serum Chromogranin A (CgA) | Other lab findings | CT scan | MRI | Utrasounography | Other diagnostic studies and imaging modalities | |||
Appendix cancer | Adenocarcinoma1 | +/- | -/+ | Constipation |
|
- | - |
|
- |
|
|
|
|
Positron emission tomography (PET) | Gross pathology:
Microscopic pathology:
IHC might be positive for the following stains:
|
Carcinoid tumor2 | +/- | - | Diarrhea |
|
- | - |
|
+ |
|
|
Gross pathology:
Microscopic pathology:
IHC might be positive for S100 | ||||
Goblet cell carcinoid | + | +/- | + |
|
+/- | + |
|
+/- |
|
Unfortunately, compared to the other carcinoid tumors of appendix, GCC is more aggressive and patients with GCC generally present at higher stages. Hence, in addition to the above mentioned general findings for appendix cancers, imaging studies should look for evidences of peritoneal involvement, bone metastasis, lymphadenopathy, and metastatic lesions in ovaries and/or prostate. |
Gross pathology:
Microscopic appearance:
| ||||
Diseases | Abdominal pain | Change in girdle size | Change in bowel habits | Other symptoms | Abdominal mass | Abdominal tenderness | Other physical examination findings | Urinary 5-hydroxyindoleacetic acid (5-HIAA) and/or Serum Chromogranin A (CgA) | Other lab findings | CT scan | MRI | Utrasounography | Other diagnostic studies and imaging modalities | Histopathology | |
Appendix Mucocele | Mucosal hyperlasia | - | - | - |
|
- | +/- | N/A | - | N/A |
|
|Rounded right iliac fossa mass
|
|
N/A | Similar to hyperplastic colon polyp |
Simple or retention cyst | - | - | - | - | +/- | - | - | N/A | Degenerative epithelial changes because of obstruction | ||||||
Mucinous cystadenomas | +/- | +/- | +/-Diarrhea
+/-Constipation |
|
+/- | +/- | If develop pseudomyxoma peritonei:
|
- |
|
| |||||
Mucinous cystadenocarcinomas | +/- | +/- | +/-Diarrhea
+/-Constipation |
+/- | +/- | - | - |
|
| ||||||
Diseases | Abdominal pain | Change in girdle size | Change in bowel habits | Other symptoms | Abdominal mass | Abdominal tenderness | Other physical examination findings | Urinary 5-hydroxyindoleacetic acid (5-HIAA) and/or Serum Chromogranin A (CgA) | Other lab findings | CT scan | MRI | Utrasounography | Other diagnostic studies and imaging modalities | Histopathology | |
Ovarian cancer | +/- | +/- | +/-Constipation |
|
+ | +/- |
|
- |
|
|
|
|
N/A | Depends on the tumor type. You may find the details here. | |
Colorectal cancer | +/- | +/- | +/-Diarrhea
+ Constipation |
|
+ | +/- | Colonoscopy
Adenocarcinoma
Carcinoids
|
-/+(Carcinoid tumors) |
|
luminal narrowing, intestinal wall thickening,intussusception, bowel obstruction, hepatic metastases, intestinal perforation,enlarged lymph nodes |
|
Generally not recommended: may evaluate liver metastasis or presence of fluid in abdominal cavity, but it is neither sensitive nor specific. | PET scan, Endoscopy, Colonoscopy,
Barium enema |
| |
Pseudomyxoma peritonei | + | + | +/-Diarrhea
+/-Constipation |
Bloating | - | + | Ascites
Shifting dullness |
- |
|
|
Characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. MRI has better sensitivity in detecting ascites fluid and mucocele. |
|
18F-FDG PET scan | ||
Carcinoid syndrome | -/+ | - | Diarrhea | Flushing
Palpitation Dyspnea |
- | - |
|
+ | Depends on the tumor type:
|
Depends on the primary tumor location and type | Depends on the primary tumor location and type | Depends on the primary tumor location and type |
|
| |
Appendicitis 3 | Periumbelical, RLQ | - | +/- Diarrhea
+ Constipation |
Nausea & vomiting,decreased appetite
Anorexia |
+/- | + |
|
- |
|
Appendiceal wall thickening /perforation
peri-appendiceal inflammation, fluid accumulation,fat stranding |
Increased fluid signal on T2 weighted sequence | Evidences of inflammation
|
Tc-99m labeled anti-CD15 antibodies | Evidences of inflammation | |
Diseases | Abdominal pain | Change in girdle size | Change in bowel habits | Other symptoms | Abdominal mass | Abdominal tenderness | Other physical examination findings | Urinary 5-hydroxyindoleacetic acid (5-HIAA) and/or Serum Chromogranin A (CgA) | Other lab findings | CT scan | MRI | Utrasounography | Other diagnostic studies and imaging modalities | Histopathology |
1 Adenocarcinomas usually present with appendicitis, barely they might present with Pseudomyxoma peritonei; meanwhile Pseudomyxoma peritonei is more prevalent in perforated mucocele, goblet cell tumor or high stages of adenocarcinoma.
2 Generally appendix carcinoids are asymptomatic, they were only become symptomatic if they metastasize to the liver, or in rare cases make an obstruction and present with appendicitis which is quit uncommon in appendiceal carcinoids compared to appendiceal adenocarcinoma. Any patient with carcinoid syndrome should be evaluated for appendix carcinoids.
3 Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer.
*Abbreviations: RLQ: Right Lower Quadrant, AFP:Alpha Fetoprotein, HCG: Human chorionic gonadotropin, LDH: Lactate Dehydrogenase, CEA: Carcinoembryonic antigen, CA 125: Cancer antigen 125